Azelby Robert
Director at ADCT; EVP & Chief Commercial Officer at Juno Therapeutics, Inc.
- Sold, on record
- $13.7M
- Dollars the filings state
- Form 4 sales
- 11
- Latest Jun 17, 2024
- Form 144 notices
- 1
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ADCTADC Therapeutics SADirector
- Juno Therapeutics, Inc.EVP & Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Juno Therapeutics, Inc.190,613 shares
- ADCT6,995 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Juno Therapeutics, Inc.Plan not statedDec 18, 2017 2017
Sold 1,816 shares at $44.96 ($82k)
Azelby Robert, EVP & Chief Commercial Officer
Sold 2.5% of holdings ($3.3M position)70,832 shares left0.1x usual sizeFiling
- 2 Form 4 sale Juno Therapeutics, Inc.UnusualJan 17, 2018 +30 days
Sold 29,131 shares at $68.61 ($2M)
Azelby Robert, EVP & Chief Commercial Officer
Sold 29.1% of holdings ($6.9M position)70,832 shares left2.3x usual sizeFiling
- 3 Form 4 sale Juno Therapeutics, Inc.UnusualJan 22, 2018 +5 days
Sold 102,539 shares at $86.25 ($8.8M)
Azelby Robert, EVP & Chief Commercial Officer
Sold 59.1% of holdings ($15M position)70,832 shares left8x usual sizeFiling
- 4 Form 4 sale Juno Therapeutics, Inc.Plan not statedFeb 1, 2018 +10 days
Sold 4,167 shares at $85.78 ($357k)
Azelby Robert, EVP & Chief Commercial Officer
Sold 4.1% of holdings ($8.6M position)96,471 shares left0.3x usual sizeFiling
- 5 Form 4 sale Juno Therapeutics, Inc.Plan not statedFeb 8, 2018 +7 days
Sold 3,497 shares at $85.77 ($300k)
Azelby Robert, EVP & Chief Commercial Officer
Sold 3.6% of holdings ($8.3M position)93,771 shares left0.3x usual sizeFiling
- 6 Form 4 sale Juno Therapeutics, Inc.Plan not statedFeb 12, 2018 +4 days
Sold 4,157 shares at $85.55 ($356k)
Azelby Robert, EVP & Chief Commercial Officer
Sold 4.4% of holdings ($8M position)89,614 shares left0.3x usual sizeFiling
- 7 Form 4 sale ADCTNo planJun 17, 2024 +2317 days
Sold 6,995 shares at $2.89 ($20k)
Azelby Robert, Director
No 10b5-1 planSold 11.7% of holdings ($173k position)53,005 shares leftFirst sale on recordFollows a Form 144Filing
- 8 Form 144 notice ADCTNoticeJun 17, 2024 same day
Filed to sell 6,995 shares ($20k)
Azelby Robert, Director
No 10b5-1 planFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (12)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 | Jun 18, 2024 | ADCT | Director | Form 144 notice | 6,995 | $20k | Notice | SEC | |
| Jun 17, 2024 | Jun 18, 2024 | ADCT | Director | Form 4 sale | 6,995 | $20k | 11.7% | No plan | SEC |
| Feb 12, 2018 | Feb 14, 2018 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 4,157 | $356k | 4.4% | Plan not stated | SEC |
| Feb 8, 2018 | Feb 9, 2018 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 3,497 | $300k | 3.6% | Plan not stated | SEC |
| Feb 1, 2018 | Feb 2, 2018 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 4,167 | $357k | 4.1% | Plan not stated | SEC |
| Jan 22, 2018 | Jan 24, 2018 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 102,539 | $8.8M | 59.1% | Unusual | SEC |
| Jan 17, 2018 | Jan 19, 2018 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 29,131 | $2M | 29.1% | Unusual | SEC |
| Dec 18, 2017 | Dec 20, 2017 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 1,816 | $82k | 2.5% | Plan not stated | SEC |
| Nov 2, 2017 | Nov 3, 2017 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 6,666 | $366k | 8.3% | Plan not stated | SEC |
| Sep 13, 2017 | Sep 14, 2017 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 12,850 | $578k | 25.6% | Unusual | SEC |
| Aug 29, 2017 | Aug 31, 2017 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 12,869 | $514k | 20.4% | Plan not stated | SEC |
| Nov 10, 2016 | Nov 10, 2016 | Juno Therapeutics, Inc. | EVP & Chief Commercial Officer | Form 4 sale | 12,921 | $312k | 26.6% | Unusual | SEC |